維持用静脈内免疫グロブリン療法に関連するエンボリック・イシェミック・ストローク
Ryoji Miyano1, Yu Yoshida1, Kazuki Fujita1
1Department of Neurology, Jichi Medical University, Saitama Medical Center, Japan.
Internal medicine (Tokyo, Japan)
|February 23, 2026
まとめ
慢性炎症性脱ミエリン化ポリラジキュロネウロパシー (CIDP) に対する静脈内免疫グロブリン (IVIG) 治療は,まれに栓塞性脳卒中につながる可能性があります. このケースは,IVIG治療を長期にわたって受けている低リスクの患者でも,警戒の重要性を強調しています.
科学分野:
- 神経学 神経学とは
- 免疫学 免疫学とは
- 血管医学 血管医学とは
背景:
- 慢性炎症性脱ミエリン性ポリラジキュロネウロパシー (CIDP) は,外周神経に影響する珍しい自己免疫疾患です.
- 静脈内免疫グロブリン (IVIG) は,CIDPの一般的な治療法であり,一般的に安全と考えられています.
- CIDPの症状を管理するために,長期のIVIGメンテナンス療法はしばしば必要である.
研究 の 目的:
- CIDPに対する長期IVIG治療中に発生したエンボリック・イシュケミック・ストロックの珍しい症例を報告する.
- 治療がよく耐える場合でも,深刻な有害事象の可能性を強調する.
- メンテナンスIVIGを受けている患者の継続的な警戒の必要性を強調する.
主な方法:
- CIDPを患った51歳の男性患者の症例報告.
- 患者の病歴とIVIG治療経路の詳細なレビュー.
- 神経イメージング (脳MRI) で,栓塞性心臓発作を確認する.
- 伝統的な脳卒中リスク因子と代替的血栓源の評価.
主要な成果:
- 患者は,第112回IVIG注入の直後に急性栓塞性性不全性脳卒中を経験しました.
- 脳卒中または他の栓塞性原因の伝統的なリスク要因は特定できませんでした.
- 脳卒中は,IVIGを長年にわたって耐えてきたにもかかわらず起こりました.
結論:
- 栓塞性脳卒中は,CIDPに対する長期IVIG治療の潜在的な合併症であるが,まれである.
- このリスクは,若く,低リスクの個人にさえも存在します.
- 医療従事者は,メンテナンスIVIGを受けている患者の神経学的イベントに対する警戒を保つべきである.
関連する概念動画
Venous Thrombosis III: Interprofessional Care
400
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
400
Myocarditis III: Medical Management
251
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
251
Venous Thrombosis IV: Nursing Management
288
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
288
Myocarditis IV: Nursing Management
286
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
286
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Myasthenia Gravis: Overview and Treatment
3.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.1K


